NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/16/2023
Back to search
Official data from USPTO
HEMGENIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
07/08/2023
Trademark type
Combined
Nice classes
5
Filing date
09/20/2021
Registration date
05/16/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/16/2023
Last transaction
07/08/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
16
Owner location
King of Prussia, PA, US
Examiner
MCCAULEY, BRENDAN
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of "HEMGENIX" to the right of a helix design.
Holders and representatives
Holders
CSL Behring L.L.C.
Representatives
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in gene therapy and cell therapy for the treatment of hemophilia
Publications
History of USPTO decisions and trademark events.
25 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/16/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/28/2023
PUBO
PUBLISHED FOR OPPOSITION
02/28/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/20/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/19/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/19/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/19/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/05/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/05/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/30/2022
GNSL
LETTER OF SUSPENSION E-MAILED
12/30/2022
CNSL
SUSPENSION LETTER WRITTEN
12/30/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/27/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/27/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/27/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/27/2022
GNRT
NON-FINAL ACTION E-MAILED
06/27/2022
CNRT
NON-FINAL ACTION WRITTEN
06/27/2022
DOCK
ASSIGNED TO EXAMINER
06/22/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/26/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/23/2021
NWAP
NEW APPLICATION ENTERED
09/23/2021
Continuous trademark protection
Get notified about every new filing that threatens HEMGENIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.